Vectura Group has announced the acquisition of Activaero, a German pharmaceutical technology company focused on respiratory diseases, and a fundraising to develop Activaero's lead product.The €130m (£108m) purchase, which will be funded through a combination of existing cash and equity, is expected to result in double-digit investment returns and take the company into the nebuliser market. Vectura will also benefit from enhanced medium- and long-term growth profile, it said, with accelerated revenue growth and its earnings before interest, tax, depreciation and amortisation (EBITDA) growth remaining broadly in-line over a five-year period. The group also announced plans to raise cash via the placing of 33.6m ordinary shares, equal to around 9.9% of the existing issued capital, at a to-be-deterined price for the development of Activaero's lead asset, Favolir, and to launch and/or partner Favolir in the EU and US markets. At the current share price of 158p, the placing would raise around £53m.Any remaining funds would be used for the development of the group's pipeline.Dr. Chris Blackwell, Chief Executive of Vectura, commented: "We are determined to build further value in our company and this transaction represents an important step towards building a sustainable specialty pharma business. "The acquisition is highly complementary to Vectura's core capabilities, in-line with our strategic priorities and, I believe, will enable us to build a therapeutic specialist in airways diseases."The transaction is expected to create a "much stronger entity", with a balanced offering of products and technologies. "Our considerably deeper pipeline and new partnerships will provide us with the opportunity to drive organic growth. We see significant value in the combination of our respective respiratory expertise and believe that the combined company is well positioned to extract even more value from our broader technology base and potentially retain greater economics from pipeline assets."NR